This presentation provided an in-depth overview of the DelSiTech silica matrix technology, a novel approach to drug delivery. This technology enabled the physical encapsulation of various active pharmaceutical ingredients (APIs), including small molecules, peptides, antisense oligonucleotides, large biologic proteins, and vaccines, into biodegradable silica. The encapsulation process involved combining the API with silica oligomers, which prevented aggregation and allowed for high drug loading. The release of the API was controlled by the erosion of the silica matrix, rather than the solubility of the API.
Three examples of drug delivery were highlighted: peptides, antisense oligonucleotides, and monoclonal antibodies. Each example demonstrated the technology's ability to provide long-acting controlled release through different methods such as subcutaneous injection and topical eye delivery. The technology could achieve high concentrations of APIs (up to 400 milligrams per millilitre) without aggregation, as the encapsulated APIs remained stable in a dry form inside the microparticles. This stability protected them from the external environment until they were released.
The versatility and adaptability of the technology were emphasised, as it could be applied to various types of molecules, from small molecules to large proteins. The technology offered true control of API release based on erosion, typically without burst release, and could be used for long-acting injectables that needed to be sterile. The presentation also discussed the company's collaborations with various partners in different fields, including ocular disease and biological oncology.
Overall, the presentation highlighted the innovative aspects of the DelSiTech silica matrix technology and its potential applications in drug delivery. The technology's ability to provide controlled release, high drug loading, and stability made it a promising solution for various pharmaceutical needs.
